产品编号 | IHC0685H |
英文名称 | Human P63 Ready-To-Use IHC Kit |
中文名称 | 人肿瘤抑制基因p63即用型免疫组化试剂盒 |
别 名 | AIS; B(p51A); B(p51B); EEC3; KET; LMS; NBP; OFC8; p40; p51; p53CP; P63; P73H; P73L; RHS; SHFM4; TP53CP; TP53L; TP63; TP73L |
适用样品基质 | FFPE tissue |
保存条件 | Please store components at the temperatures indicated on the individual tube labels. The kit is stable for 6 months from the date of receipt. |
产品介绍 |
TP63 (tumor protein 63) acts as a sequence-specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform-specific activity. Isoform 2 activates RIPK4 transcription. TP63 may be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. It is involved in Notch signaling by inducing JAG1 and JAG2. TP63 plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. TP63 is required for limb formation from the apical ectodermal ridge. It also activates transcription of the p21 promoter. Mutations affecting the gene can result in Acro-dermato-ungual-lacrimal-tooth syndrome, ankyloblepharon-ectodermal defects-cleft lip/palate, ectrodactyly ectodermal dysplasia, split-hand/foot malformation 4, limb-mammary syndrome, ectodermal dysplasia - Rapp-Hodgkin type, and orofacial cleft 8. SWISS: Q9H3D4 Gene ID: 8626 |
产品图片 |
Immunohistochemical analysis of paraffin embedded Human breast cancer tissue slide using IHC0685H (Human P63 Kit).
Immunohistochemical analysis of paraffin embedded Human mammary gland tissue slide using IHC0685H (Human P63 Kit).
|
1、抗体溶解方法 | |
2、抗体修复方式 | |
3、常用试剂的配制 | |
4、免疫组化操作步骤 | |
5、免疫组化问题解答 | |
6、Western Blotting 操作步骤 | |
7、Western Blotting 问题解答 | |
8、关于肽链的设计 | |
9、多肽的溶解与保存 | |
10、酶标抗体效价测定程序 | |